Accessibility Menu
TransMedics Group Stock Quote

TransMedics Group (NASDAQ: TMDX)

$147.03
(1.2%)
+1.77
Price as of March 2, 2026, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$147.03
Daily Change
(1.2%) +$1.77
Day's Range
$137.70 - $147.77
Previous Close
$147.03
Open
$138.50
Beta
1.56
Volume
33,838
Average Volume
758,314
Market Cap
$5.0B
Market Cap / Employee
$147.00M
52wk Range
$62.07 - $156.00
Revenue
N/A
Gross Margin
0.60%
Dividend Yield
N/A
EPS
$4.86
CAPs Rating
N/A
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

TransMedics Group Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TMDX+92.61%+292.42%+31.45%+557%
S&P+15.57%+80.16%+12.49%+136%

TransMedics Group Company Info

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

News & Analysis

Financial Health

General

Q4 2025YOY Change
Revenue$160.76M32.2%
Gross Profit$93.41M29.7%
Gross Margin58.11%-1.1%
Market Cap$4.16B98.7%
Market Cap / Employee$4.63M0.0%
Employees89823.4%
Net Income$105.38M1436.9%
EBITDA$28.74M100.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q4 2025YOY Change
Net Cash$488.37M45.1%
Accounts Receivable$84.28M-13.8%
Inventory48.95.0%

Liabilities

Q4 2025YOY Change
Long Term Debt$505.97M-1.9%
Short Term Debt$13.31M388.1%

Ratios

Q4 2025YOY Change
Return On Assets19.55%14.9%
Return On Invested Capital-14.74%8.5%

Cash Flow

Q4 2025YOY Change
Free Cash Flow$19.00M213.7%
Operating Free Cash Flow$34.51M75.5%

Valuation

MetricQ1 2025Q2 2025Q3 2025Q4 2025YoY Change
Price to Earnings49.4569.3045.3225.05-59.42%
Price to Book9.8917.0212.0111.6917.31%
Price to Sales5.5010.238.078.2265.38%
Price to Tangible Book Value10.5217.9412.5412.1613.97%
Price to Free Cash Flow TTM313.2437.9037.27-
Enterprise Value to EBITDA86.17128.26153.41174.315.04%
Free Cash Flow Yield0.3%2.6%2.7%-
Return on Equity23.0%28.2%32.5%54.2%179.72%
Total Debt$518.41M$518.82M$519.35M$519.28M0.19%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.